Research

Agenda

THE JAK-STAT PATHWAY: 20 YEARS FROM DISCOVERY TO DRUGS

7:30 a.m.	Continental Breakfast / Check-in
8:15 a.m. – 8:25 a.m.	Welcome	John O’Shea (NIH/NIAMS)
8:25 a.m. – 9:15 a.m.	Plenary: Where JAK-STAT Came from and One Place I Hope It Goes	James Darnell (Rockefeller University)

Session I

Jaks, Signaling & Inhibitors (Chair, John O’Shea, NIH/NIAMS)

9:15 a.m. - 9:45 a.m.	Probing Cytokine Receptor Signaling through Imaging and Protein Engineering	K. Christopher Garcia (Stanford University)
9:45 a.m. – 10:15 a.m.	Jak Inhibitors: That’s a Fact, Jak!	John O’Shea (NIH/NIAMS)
10:15 a.m. – 10:45 a.m.	Tofacitinib: An Investigational, Selective JAK Inhibitor for Treatment of Autoimmune Diseases	Samuel Zwillich (Pfizer)
10:45 a.m. – 11:15 a.m.	BREAK
11:15 a.m. – 11:45 a.m.	JAK/STAT Signaling and MPN Phenotype	Tony Green (Cambridge Institute for Medical Research)
11:45 a.m. – 12:15 p.m.	Janus Kinase Inhibition: Myelofibrosis and Beyond	Jordan Fridman (Incyte)
12:15 p.m. – 1:15 p.m.	LUNCH

Session II

Jaks, Signaling & Inhibitors II (Chair, James Darnell, Rockefeller University)

1:15 p.m. – 1:45 p.m.	Therapeutic Opportunities Based on Oncogenic Jak Kinase Signaling in Lymphoma	Louis Staudt (NIH/NCI)
1:45 p.m. – 2:15 p.m.	Targeting JAK-STAT Signaling for Cancer Therapy	Richard Jove (City of Hope)
2:15 p.m. – 2:45 p.m.	Characterization of the Pseudokinase Domain of JAK2	Olli Silvennoinen (University of Tampere, Finland)
2:45 p.m. – 3:00 p.m.	Preclinical Pharmacology and Early Clinical Evaluation of GLPG0634, a Selective Jak1 Inhibitor for the Treatment of Rheumatoid Arthritis	Gerben van't Klooster (Galapagos NV)
3:00 p.m. – 3:15 p.m.	Targeting STAT5 in CML: Mechanism-of-action of JAK2 Tyrosine Kinase Inhibitors Unmask a Direct BCR/ABL-STAT5 Axis	Veronika Sexl (Veterinary University of of Vienna)
3:15 p.m. – 3:45 p.m.	BREAK

Session III

Biology of STATS (Chair, George Stark, Lerner Institute, Case Western)

3:45 p.m. – 4:15 p.m.	To Modify or Not to Modify, That Is the STAT Question	George Stark (Lerner Institute)
4:15 p.m. – 4:45 p.m.	Jak-STAT Pathway and Obesity	Andrew Larner (Virginia Commonwealth University)
4:45 p.m. – 5:15 p.m.	Nongenomic Functions of STAT3	David Levy (NYU)
5:15 p.m. – 5:45 p.m.	Dynamics of STAT3 Nuclear Trafficking	Nancy Reich (Stony Brook University)
5:45 p.m. – 6:00 p.m.	Protein Kinase CK2 Functions as a Positive Regulator of the JAK/STAT and NF-kappaB Pathways	Tika Benveniste (University of Alabama)
6:00 p.m. – 6:15 p.m.	Stat2 Directs the Stat1-independent Suppression of Legionella pneumophila Growth by IFN-Is	Christian Schindler (Columbia University)

7:30 a.m.

Continental Breakfast

Session IV

STATs, Cancer & STAT Inhibitors (Chair, David Levy, NYU)

8:15 a.m. – 8:45 a.m.	The Transcription Factors Stat3 and Stat5 Are Potent Oncogenes and Promising Drug Targets	Bernd Groner (Frankfurt)
8:45 a.m. – 9:15 a.m.	Selective Inhibition of Stat3 Phosphorylation with Phosphopeptidomimetic Prodrugs Targeting the SH2 Domain Inhibits the Growth of Breast Tumor Xenografts in Mice	John McMurray (MD Anderson Cancer Center)
9:15 a.m. – 9:45 a.m.	Chemical Biology Approaches to Developing STAT Modulators	David Frank (Harvard University)
9:45 a.m. – 10:15 a.m.	A Division of Labor between STAT5A and STAT5B in CML Pathophysiology	Isabelle Dusanter-Fourt (INSERM/ University Paris Descartes)
10:15 a.m. – 10:45 a.m.	Nonconventional Approaches to Inhibition of Jak/STAT Signaling	Nadya Tarasova (NCI)
10:45 a.m. – 11:15 a.m.	BREAK

Session V

STATs in Immunoregulation (Chair, Warren Leonard, NIH/NHLBI)

11:15 a.m. – 11:45 a.m.	STAT4 Play	Mark Kaplan (Indiana University)
11:45 a.m. – 12:15 p.m.	New STATs on Memory CD4 T Cell Development	Susan Kaech (Yale School of Medicine)
12:15 p.m. – 12:45 p.m.	STAT Mediated Regulation of Th Cell Differentiation	Riitta Lahesmaa (Turku Centre for Biotechnology, University of Turku, Finland)
12:45 p.m. – 1:15 p.m.	STAT5 as a Modulator of Th Differentiation	Warren Leonard (NIH/NHLBI)
1:15 p.m. - 2:15 p.m.	LUNCH

Session VI

Biology of STATs II (Chair, Lothar Hennighausen, NIH/NIDDK)

2:15 p.m. – 2:45 p.m.	STAT5: From Basel to Bethesda and Beyond	Lothar Hennighausen (NIH/NIDDK)
2:45 p.m. – 3:15 p.m.	Role of Stats in Lineage Determination and Cell Death Regulation in Mammary Gland	Christine Watson (Cambridge University)
3:15 p.m. – 3:45 p.m.	Landscape of STAT-dependent Histone Epigenetic Modification in T Helper Cell Specification	Yukka Kanno (NIH/NIAMS)
3:45 p.m. – 4:15 p.m.	Epigenetic Regulation of Interferon-gamma Signaling	Rod Bremner (Toronto Western Hospital)
4:15 p.m. – 4:45 p.m.	What We Learned from Drosophila JAK & STAT	Willis Li (UCSD)
4:45 p.m. – 5:15 p.m.	Activated Stat is a Supercompetitor That Acts Independently of Myc, YAP, Wnt and Ribosome Biogenesis	Erika Bach (NYU)
5:15 p.m. – 5:45 p.m.	Localized JAK/STAT Signaling Maintains Tissue Shape during Morphogenesis	Martin Zeidler (University of Sheffield)
5:45 p.m. – 6:00 p.m.	Chromatin–associated Phosphorylation of Stat Transactivation Domains Is Catalyzed by Cdk8 of the Mediator Complex	Pavel Kovarik (University of Vienna)
6:00 p.m. – 6:15 p.m.	An Essential Role of Stat3 in PI3K-induced Oncogenic Transformation	Jonathan Hart (The Scripps Research Institute)
6:15 p.m.	POSTER SESSION / RECEPTION

ENTERTAINMENT: CIT Band

7:30 a.m.

Continental Breakfast

Session VII

STATs & Cancer (Chair, Richard Jove, City of Hope)

8:15 a.m. – 8:45 a.m.	STAT3 in Cancer Inflammation and Immunity	Hua Yu (City of Hope Medical Center)
8:45 a.m. – 9:15 a.m.	STAT3, Auto-immunity and Cancer: When Does Enough Become Too Much?	Valeria Poli (University of Turin)
9:15 a.m. – 9:45 a.m.	The Tumorigenic Role of Stat3 in T-cell Anaplastic Large Cell Lymphoma	Giorgio Inghirami (University of Turin)
9:45 a.m. – 10:15 a.m.	Single Cell Signaling & STAT Physiology in Cancer and Inflammation by Isotopic Mass Cytometry	Garry Nolan (Stanford University)
10:15 a.m. – 10:45 a.m.	BREAK
10:45 a.m. – 11:15 a.m.	STAT3 Targeting in Head & Neck Cancer	Jennifer Grandis (University of Pittsburgh)
11:15 a.m. – 11:45 a.m.	Stat5: Oncogene and Tumor Suppressor	Richard Moriggl (Boltzmann Institute)
11:45 a.m. – 12:15 p.m.	STAT3 as Inducer of Immune Evasion and Epigenetic Silencing of Tumor Suppressor Genes	Mariusz Wasik (University of Pennsylvania)
12:15 p.m. – 12:45 p.m.	The Good and Evil Faces of the Janus Kinases in Heath and Disease	Thomas Waldmann (NIH/NCI)
12:45 p.m. – 1:00 p.m.	Targeting the IL-6/Jak Pathway in Breast Cancer	Jacqueline Bromberg (MSKCC)
1:00 p.m. – 2:00 p.m.	LUNCH

Session VIII

STATs & Infectious Disease (Chair, Manfred Boehm, NIH/NHLBI)

2:00 p.m. - 2:30 p.m.	Inborn Errors of Human STAT1 Immunity	Jean-Laurent Casanova (Rockefeller University)
2:30 p.m. – 3:00 p.m.	Interferon and JAK-STAT Regulation by Cells and Viruses	Curt Horvath (Northwestern University)
3:00 p.m. – 3:30 p.m.	Hyper IgE Syndrome: From Wound Healing to Cell Reprogramming	Manfred Boehm (NIH/NHLBI)
3:30 p.m. – 4:00 p.m.	Modulating STAT Levels for Regulating Cytokine Effects During Viral Infections: Lessons from NK cells	Christine Biron (Brown University)
4:00 p.m. – 4:30 p.m.	STAT3 & Job’s Syndrome	Steve Holland (NIH/NIAID)

ADJOURN